# Medpace Holdings, Inc. – Consensus ‘buy’ rating and 16.7% Upside Potential

- Link: https://www.directorstalkinterviews.com/medpace-holdings-inc.consensus-buy-rating-and-16.7-upside-potential/4121130252
- Published: 2023-10-20T15:17:36+01:00
- Author: Charlotte Edwards

**Medpace Holdings, Inc.** which can be found using ticker (MEDP) have now 4 confirmed
analysts covering the stock with the consensus suggesting a rating of ‘buy’. The
target price High/Low ranges between 273 and 265 suggesting an average Analsyt target
price of $269.50. Given that the stocks previous close was at $231.02 this indicates
there is a potential upside of 16.7%. It’s also worth noting that there is a 50 
day moving average of $255.23 and the 200 moving average now moves to $224.88. The
market cap for the company is 7.02B. The current share price for the company is:
229.56 USD

 The potential market cap would be $8,184,620,527 based on the market consensus.

The company is not paying dividends at this time.

Other points of data to note are a P/E ratio of 27.62, revenue per share of 54.09
and a 14.64% return on assets.

Medpace Holdings, Inc. is a global provider of clinical research-based drug and 
medical device development services. The Company is focused on providing scientifically
driven outsourced clinical development services to the biotechnology, pharmaceutical
and medical device industries. The Company partners with pharmaceutical, biotechnology,
and medical device companies in the development and execution of clinical trials.
The Company’s drug development services focuses on full-service Phase I-IV clinical
development services and include development plan design, coordinated central laboratory,
project management, regulatory affairs, clinical monitoring, data management and
analysis, pharmacovigilance new drug application submissions, and post-marketing
clinical support. It also provides bio-analytical laboratory services, clinical 
human pharmacology, imaging services, and electrocardiography reading support for
clinical trials. Its operations are based in North America, Europe, and Asia.

Share on: